ICU AI Analysis Overview
Keys for Bullish View
- Value≥4
- Dividend≥2
Analysis Conclusion
With insufficient quarterly financial data released by the company, we're unable to provide a rating.
ICU Current Performance
11.53%
Seastar medical holding corp
1.19%
Avg of Sector
1.11%
S&P500
Top 10 High Relevance to ICU
| Symbol | Company Name | Value | Trend | Swing Trading | Whale Interest | Dividend | Add to Watchlist |
|---|---|---|---|---|---|---|---|
IRIX | Iridex corp | 2 | 1 | 4 | 1 | 1 | |
IART | Integra lifesciences holdings corporation | 3 | 3 | 4 | 2 | 1 | |
NUWE | Nuwellis inc | 3 | 2 | 2 | 1 | 1 | |
ACON | Aclarion inc | - | 3 | 2 | 1 | 1 | |
WRBY | Warby parker inc | - | 3 | 3 | 3 | 1 |
- IRIX Iridex corpValue 2Trend 1Swing Trading 4Whale Interest 1Dividend 1See more
ICU Profile
SeaStar Medical Holding Corp Formerly known as LMF Acquisition Opportunities Inc. SeaStar Medical Holding Corporation is a commercial-stage medical technology company. The Company is focused on developing extracorporeal therapies to reduce the consequences of hyperinflammation on vital organs. The Company's technologies rely on science to provide life-saving solutions to critically ill patients. The Company develops and commercializes cell-directed extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company uses its Selective Cytopheretic Device (SCD) technology platform to clinically validate several acute organ injury indications, including kidneys and lungs. Its investigational SCD is an extracorporeal synthetic membrane device designed to integrate into existing continuous renal replacement therapy (CRRT) systems that are commonly installed in hospitals throughout the United States.